Literature DB >> 25082649

Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange.

Takuya Fujimaru1, Shuichi Ito2, Hiroshi Masuda3, Shinji Oana3, Koichi Kamei1, Akira Ishiguro3, Hitoshi Kato4, Jun Abe5.   

Abstract

The pathogenesis of coronary artery aneurysm (CAA) formation in Kawasaki disease (KD) remains unknown. However, inflammatory cytokines are thought to play an important role in KD. Patients with intravenous immunoglobulin (IVIG)-resistant KD are more likely to develop CAA. For such refractory patients, steroids and emerging infliximab (IFX) are used; however, further verification is required for their efficacy and safety. Plasma exchange (PE), which removes various inflammatory cytokines, has been used in Japan for over 15 years to prevent CAA in IVIG-resistant KD patients. The sequential change in inflammatory cytokines during the time course of PE has yet to be investigated. In this study, we measured plasma levels of 13 cytokines in nine children with IVIG-resistant KD before the start of PE (day 0: D0), as well as at 1 or 2 days (D1/2), and 4 or 5 days (D4/5) after starting PE. The median age of onset was 8 months (range: 3-53 months). Before PE, patients were treated with IVIG (median dose: 4 g/kg, range: 3-4 g/kg). The median starting period of PE was 8 days after the onset of fever (range: 6-21 days), while its duration was 3 days (range: 2-5 days). Among the 13 cytokines, interleukin-6, tumor necrosis factor-α, tumor necrosis factor receptor I (TNFR1), TNFR2, granulocyte colony-stimulating factor, and IL-17 were significantly lower at D4/5 compared with D0 and/or D1/2, reflecting the potential central efficacy of PE. While three patients developed moderate CAA, their condition regressed within 1 year. The removal of inflammatory cytokines could be the central efficacy of PE against refractory KD.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Coronary artery aneurysm; Cytokine; Immunoglobulin; Kawasaki disease; Plasma exchange

Mesh:

Substances:

Year:  2014        PMID: 25082649     DOI: 10.1016/j.cyto.2014.07.003

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  14 in total

Review 1.  Treatment Options for Resistant Kawasaki Disease.

Authors:  Linny Kimly Phuong; Nigel Curtis; Peter Gowdie; Jonathan Akikusa; David Burgner
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

Review 2.  Kawasaki disease: etiopathogenesis and novel treatment strategies.

Authors:  Shreya Agarwal; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2016-09-13       Impact factor: 4.473

3.  Markedly elevated CD64 expression on neutrophils and monocytes as a biomarker for diagnosis and therapy assessment in Kawasaki disease.

Authors:  Sho Hokibara; Norimoto Kobayashi; Keiko Kobayashi; Tomonari Shigemura; Haruo Nagumo; Masahiro Takizawa; Takashi Yamazaki; Kazunaga Agematsu
Journal:  Inflamm Res       Date:  2016-03-28       Impact factor: 4.575

Review 4.  Vaping, SARS-CoV-2, and Multisystem Inflammatory Syndrome: A Perfect Storm.

Authors:  Esha Brar; Anish Saxena; Claudia Dukler; Fangxi Xu; Deepak Saxena; Preneet Cheema Brar; Yuqi Guo; Xin Li
Journal:  Front Pediatr       Date:  2021-05-12       Impact factor: 3.418

5.  'Emergency exit' of bone-marrow-resident CD34(+)DNAM-1(bright)CXCR4(+)-committed lymphoid precursors during chronic infection and inflammation.

Authors:  Federica Bozzano; Francesco Marras; Maria Libera Ascierto; Claudia Cantoni; Giovanni Cenderello; Chiara Dentone; Antonio Di Biagio; Giancarlo Orofino; Eugenio Mantia; Silvia Boni; Pasqualina De Leo; Antonino Picciotto; Fulvio Braido; Francesca Antonini; Ena Wang; Francesco Marincola; Lorenzo Moretta; Andrea De Maria
Journal:  Nat Commun       Date:  2015-10-05       Impact factor: 14.919

6.  Monoclonal antibody therapy for Kawasaki disease: a protocol for systematic reviews and meta-analysis.

Authors:  Osamu Nomura; Sayaka Fukuda; Erika Ota; Hiroshi Ono; Akira Ishiguro; Tohru Kobayashi
Journal:  Syst Rev       Date:  2016-04-12

7.  Risk factors and implications of progressive coronary dilatation in children with Kawasaki disease.

Authors:  Ming-Yu Liu; Hsin-Min Liu; Chia-Hui Wu; Chin-Hao Chang; Guan-Jr Huang; Chun-An Chen; Shuenn-Nan Chiu; Chun-Wei Lu; Ming-Tai Lin; Luan-Yin Chang; Jou-Kou Wang; Mei-Hwan Wu
Journal:  BMC Pediatr       Date:  2017-06-06       Impact factor: 2.125

Review 8.  Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients.

Authors:  Seena Tabibi; Tara Tabibi; Rosalynn R Z Conic; Nassim Banisaeed; Michael B Streiff
Journal:  J Intensive Care Med       Date:  2020-07-15       Impact factor: 3.510

9.  A Combination Therapy for Kawasaki Disease with Severe Complications: a Case Report.

Authors:  Yuriko Abe; Mamoru Ayusawa; Kengo Kawamura; Ryuta Yonezawa; Masataka Kato; Akiko Komori; Ryutaro Kohira; Ichiro Morioka
Journal:  Open Med (Wars)       Date:  2019-12-26

10.  Safety and efficacy of plasma exchange therapy for Kawasaki disease in children in intensive care unit: case series.

Authors:  Satoko Noguchi; Junichi Saito; Tomoyuki Kudo; Eiji Hashiba; Kazuyoshi Hirota
Journal:  JA Clin Rep       Date:  2018-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.